Major Investors Bet Big on Pfizer’s Turnaround Potential
29.11.2025 - 16:52:04Pfizer US7170811035
While Pfizer’s share price has shown limited movement in recent sessions, significant activity is unfolding behind the scenes. Prominent financial institutions are capitalizing on this apparent stagnation to make substantial purchases, repositioning their portfolios as market analysts begin to identify considerable upside potential. Is this strategic accumulation by sophisticated investors signaling a major trend reversal, or could retail investors be heading into a value trap?
Adding momentum to the institutional buying trend, the analytical firm Guggenheim has provided a fresh optimistic outlook. The firm’s analysts recently increased their price target to $35 while reaffirming their buy recommendation. This revised target suggests an approximate 36 percent Read more...
